CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical…
7 objective responses observed to date in multiple tumor types New responses reported in patients…
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage…
— Late-breaking presentation highlights preclinical data for AO-176 in T-ALL — BRISBANE, Calif., April 10,…
Preliminary data demonstrate a robust increase in HPV16+-specific T cells, including up to 8% of…
VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models First-in-human studies…
-Translational analysis of patients that do not respond to PD-(L)1 inhibitors show high pretreatment intratumoral…
Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a…
ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),…
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual…
